Clinical Trial Update: SPI-1005 for the Treatment of Meniere's Disease (Open Label) [Phase 3]

View source ↗

Summary

An open-label, Phase 3 trial of SPI-1005 for Meniere's disease is currently recruiting. The sponsor is Sound Pharmaceuticals, Incorporated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meniere Disease

Drugs mentioned

• SPI-1005

Snippet

Sponsor: Sound Pharmaceuticals, Incorporated | Conditions: Meniere's Disease, Ménière's Disease | Phase 3 | Status: RECRUITING